TSCAN THERAPEUTICS INC (TCRX) Stock Price, Forecast & Analysis
USA - NASDAQ:TCRX - US89854M1018 - Common Stock
TCRX Key Statistics, Chart & Performance
The current stock price of TCRX is 1.22 USD. In the past month the price decreased by -42.18%. In the past year, price decreased by -72.34%.
TCRX Latest News, Press Relases and Analysis
TCRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.83 | 397.78B | ||
| AMGN | AMGEN INC | 15.48 | 182.21B | ||
| GILD | GILEAD SCIENCES INC | 14.96 | 152.07B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.72 | 110.05B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.99 | 71.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 886.18 | 59.24B | ||
| INSM | INSMED INC | N/A | 40.94B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 9.53 | 23.39B | ||
| INCY | INCYTE CORP | 16.85 | 21.12B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.4 | 20.77B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.24 | 14.61B |
Related stock screener links
About TCRX
Company Profile
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. The company is headquartered in Waltham, Massachusetts and currently employs 210 full-time employees. The company went IPO on 2021-07-16. The firm is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The firm is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The firm has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
Company Info
TSCAN THERAPEUTICS INC
830 Winter Street
Waltham MASSACHUSETTS US
CEO: David Southwell
Employees: 201
Phone: 18573999500
TSCAN THERAPEUTICS INC / TCRX FAQ
What does TSCAN THERAPEUTICS INC do?
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. The company is headquartered in Waltham, Massachusetts and currently employs 210 full-time employees. The company went IPO on 2021-07-16. The firm is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The firm is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The firm has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
What is the current price of TCRX stock?
The current stock price of TCRX is 1.22 USD. The price increased by 11.93% in the last trading session.
Does TSCAN THERAPEUTICS INC pay dividends?
TCRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of TCRX stock?
TCRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists TCRX stock?
TCRX stock is listed on the Nasdaq exchange.
What do analysts say about TSCAN THERAPEUTICS INC (TCRX) stock?
14 analysts have analysed TCRX and the average price target is 8.67 USD. This implies a price increase of 610.66% is expected in the next year compared to the current price of 1.22.
Can you provide the sector and industry classification for TSCAN THERAPEUTICS INC?
TSCAN THERAPEUTICS INC (TCRX) operates in the Health Care sector and the Biotechnology industry.
TCRX Technical Analysis
TCRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TCRX. The financial health of TCRX is average, but there are quite some concerns on its profitability.
TCRX Financial Highlights
Over the last trailing twelve months TCRX reported a non-GAAP Earnings per Share(EPS) of -1.09. The EPS decreased by -3.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45.81% | ||
| ROE | -77.4% | ||
| Debt/Equity | 0.18 |
TCRX Forecast & Estimates
14 analysts have analysed TCRX and the average price target is 8.67 USD. This implies a price increase of 610.66% is expected in the next year compared to the current price of 1.22.
For the next year, analysts expect an EPS growth of -0.78% and a revenue growth 182.46% for TCRX